培妥莫單抗
單克隆抗體 | |
---|---|
種類 | ? |
目標 | MUC1 |
臨床資料 | |
商品名 | Theragyn |
給藥途徑 | 腹膜給藥 |
ATC碼 |
|
識別資訊 | |
CAS號 | 646032-04-4 |
ChemSpider |
|
培妥莫單抗(INN:pemtumomab;商品名:Theragyn),或譯潘妥莫單抗,是一種用於治療癌症的小鼠單克隆抗體。該藥物通過多態性上皮黏蛋白(PEM或MUC1)對多種類型的癌症(例如卵巢癌和腹膜癌)具有親和力,並將放射性同位素釔-90輸送到腫瘤中。[1]截至2009年,它正在進行III期臨床試驗。[2]
參考資料
- ^ Oei AL, Moreno M, Verheijen RH, Sweep FC, Thomas CM, Massuger LF, von Mensdorff-Pouilly S. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. International Journal of Cancer. October 2008, 123 (8): 1848–53. PMID 18661524. S2CID 2287723. doi:10.1002/ijc.23725 .
- ^ Clinical trial number NCT00004115 for "Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy" at ClinicalTrials.gov
- ^ Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status[失效連結]